Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
30 July 2020Website:
http://www.cerevel.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 01 Jul 2024 21:49:55 GMTDividend
Analysts recommendations
Institutional Ownership
CERE Latest News
LOS ANGELES, CA / ACCESSWIRE / July 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Cerevel board breached its fiduciary duties to shareholders.
LOS ANGELES, CA / ACCESSWIRE / June 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Cerevel board breached its fiduciary duties to shareholders.
LOS ANGELES, CA / ACCESSWIRE / June 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Cerevel board breached its fiduciary duties to shareholders.
LOS ANGELES, CA / ACCESSWIRE / June 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Cerevel board breached its fiduciary duties to shareholders.
NEW YORK, NY / ACCESSWIRE / June 25, 2024 / Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq:CERE) and AbbVie, Inc. If you invested in Cerevel Therapeutics you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/cerevel-therapeutics-holdings-inc-investigation . Claim Details: On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie.
LOS ANGELES, CA / ACCESSWIRE / June 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Cerevel board breached its fiduciary duties to shareholders.
NEW YORK, June 25, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE) and AbbVie, Inc. If you invested in Cerevel Therapeutics you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/cerevel-therapeutics-holdings-inc-investigation . Claim Details: On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie.
NEW YORK, NY / ACCESSWIRE / June 24, 2024 / Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq:CERE) and AbbVie, Inc. If you invested in Cerevel Therapeutics you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/cerevel-therapeutics-holdings-inc-investigation . Claim Details: On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie.
LOS ANGELES, CA / ACCESSWIRE / June 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Cerevel board breached its fiduciary duties to shareholders.
LOS ANGELES, CA / ACCESSWIRE / June 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Cerevel board breached its fiduciary duties to shareholders.
What type of business is Cerevel Therapeutics Holdings?
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
What sector is Cerevel Therapeutics Holdings in?
Cerevel Therapeutics Holdings is in the Healthcare sector
What industry is Cerevel Therapeutics Holdings in?
Cerevel Therapeutics Holdings is in the Biotechnology industry
What country is Cerevel Therapeutics Holdings from?
Cerevel Therapeutics Holdings is headquartered in United States
When did Cerevel Therapeutics Holdings go public?
Cerevel Therapeutics Holdings initial public offering (IPO) was on 30 July 2020
What is Cerevel Therapeutics Holdings website?
https://www.cerevel.com
Is Cerevel Therapeutics Holdings in the S&P 500?
No, Cerevel Therapeutics Holdings is not included in the S&P 500 index
Is Cerevel Therapeutics Holdings in the NASDAQ 100?
No, Cerevel Therapeutics Holdings is not included in the NASDAQ 100 index
Is Cerevel Therapeutics Holdings in the Dow Jones?
No, Cerevel Therapeutics Holdings is not included in the Dow Jones index
When does Cerevel Therapeutics Holdings report earnings?
The next expected earnings date for Cerevel Therapeutics Holdings is 02 August 2024